Stay updated with breaking news from Clinical Development Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced the first peer-reviewed publication of the Phase 3 portion of its pivotal, double-blind, randomized, placebo-controlled...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a biotechnology company focused on developing genetic medicines for severe central nervous system (CNS) disorders, today
– Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision – – Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three...
– Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision –– Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apart –– Detailed results from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, a...
Application based on results from DESTINY-PanTumor02 trial and supported by additional ENHERTU data Submission to be reviewed under FDA Real Time Oncology Review and Project Orbis If approved,...